EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Capital Expenditures (2010 - 2026)

EyePoint (EYPT) posted Capital Expenditures of $99000.0 for Q1 2026, down 96.9% sequentially from $3.2 million in Q4 2025, and up 125.0% YoY from $44000.0 in Q1 2025.

Analysis

EyePoint (EYPT) Capital Expenditures (2010 - 2026) Analysis & Trends

EyePoint has reported Capital Expenditures for 17 years, with the latest figure at $99000.0 in Q1 2026.

  • Quarterly Capital Expenditures rose 125.0% year-over-year to $99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 6.35% YoY) and the FY2025 annual result came in at $3.3 million, down 19.05% from the prior year.
  • Capital Expenditures declined to $99000.0 in Q1 2026 per EYPT's latest filing, from $3.2 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $3.2 million in Q4 2025 and troughed at -$484000.0 in Q2 2023.
  • A 5-year average of $638733.3 and a median of $218000.0 in 2022 frame the typical range for Capital Expenditures.
  • The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 814.5% in 2022, then slumped 322.02% in 2023.
  • Over 5 years, Capital Expenditures stood at $585000.0 in 2022, then sank by 182.74% to -$484000.0 in 2023, then jumped by 436.78% to $1.6 million in 2024, then jumped by 95.95% to $3.2 million in 2025, then slumped by 96.9% to $99000.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods registered $99000.0, $3.2 million, and $24000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 112.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 240.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 37.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.29 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 25.02 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 34.68 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 251.02 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 6.26 Mn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 64,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 64,000.00
Mar 31, 2026 3.36 Mn
Dec 31, 2025 986,000.00
Sep 30, 2025 798,000.00
Jun 30, 2025 1.22 Mn
Mar 31, 2025 276,000.00
Dec 31, 2024 2.16 Mn
Sep 30, 2024 1.57 Mn
Jun 30, 2024 900,000.00
Mar 31, 2024 1.19 Mn
Dec 31, 2023 883,000.00
Sep 30, 2023 1.72 Mn
Jun 30, 2023 396,000.00
Mar 31, 2023 484,000.00
Dec 31, 2022 585,000.00
Sep 30, 2022 1.20 Mn
Jun 30, 2022 218,000.00
Mar 31, 2022 149,000.00
Sep 30, 2021 131,000.00
Jun 30, 2021 25,000.00